Close Menu

The Scan

Bit More Willing

Most Americans now say they are willing to get a COVID-19 vaccine, but many are still hesitant, according to Gallup.

A new preprint indicates that immunity to SARS-CoV-2 may last for years after infection, the New York Times reports.

In Genome Research this week: unrecognized spread of SARS-CoV-2 in New York last February, assay of cell line responses to drug treatment, and more.

Pfizer launches pilot program to examine the distribution challenges facing its candidate SARS-CoV-2, according to the Guardian.

Who's First?

The Associated Press and NPR look into who may receive priority for a SARS-CoV-2 vaccine.

The New York Times reports that a suspect tied by genetic genealogy to a 1972 murder died by suicide just before a jury convicted him.

In PNAS this week: role of USF2 in refractory rheumatoid arthritis, thymus-associated cells may show up post-thymectomy in myasthenia gravis patients, and more.

Early data from Moderna suggests its candidate SARS-CoV-2 vaccine is highly effective, writes the Washington Post.

California voters have approved additional funding for the California Institute for Regenerative Medicine, according to the Associated Press.

Follow the Spread

San Diego researchers have received funds to sequence SARS-CoV-2 in the region, NBC 7 San Diego reports.

In PLOS this week: method that combines genetic and lab test results from EHRs, leptospirosis microtranscriptome profiles, and more.

The Verge reports that Pfizer and BioNTech's announcement earlier this week could portend good news from companies developing similar vaccines.

Could Miss a Few

The Guardian reports that lateral flow tests for COVID-19 being used in the UK could miss cases.

The Wall Street Journal reports that Russia has announced that its Sputnik V SARS-CoV-2 vaccine is also highly effective.

In Science this week: single-cell atlases of human fetal gene expression, chromatin accessibility; SARS-CoV-2 antibody prevalence in Kenya; more.

Science reports that the Horizon Europe budget has increased by €4 billion, but that basic research institutions may see a decline in funds next year.

Chief of Staff Choice

US President-elect Joe Biden has chosen Ronald Klain, who was the Obama Administration's Ebola Czar, as his chief of staff, the New York Times reports.

Nature News reports that the World Health Organization has released its plan to search for the origins of SARS-CoV-2.

In Nature this week: mammalian genomes give insight into selection, multiple-genome alignment program, and more.

Pretty Vaccine Penny

Estimates suggest Pfizer and BioNTech could make nearly $13 billion from sales of their SARS-CoV-2 vaccine, according to the Guardian.

Loss of Workers

The Chronicle of Higher Education reports there are 484,000 fewer workers at private and public colleges and universities in the US since the pandemic began.

The New York Times reports that one doctor who set up COVID-19 testing sites tested for additional infections and billed for that more expensive test.

In Genome Biology this week: mouse model for determining immunotherapy response, genomic changes that occur with non-small cell lung cancer metastasis, and more.

US President-elect Joe Biden has named the members of his COVID-19 advisory board, Vox reports.

Brazil halts a late-stage clinical trial of a coronavirus vaccine following a report of an adverse reaction in a participant, the Financial Times reports.

Pages

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.